More News! 9 Nov 2022 Wyss Center’s ABILITY system to improve quality of life for people with severe paralysis The Wyss Center for Bio and Neuroengineering has shared the latest signals recorded by its fully plantable ABILITY brain computer interface (BCI) at a Society for Neuroscience meeting. ABILITY is designed to improve quality of life and independence for people with severe paralysis and demonstrates safety and efficacy in pre-clinial trials. New details of the […] November 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2022 Acticor Biotech enrolls first U.S. patient in study for people with acute ischemic stroke The first U.S. patient was enrolled in a study evaluating glenzocimab in those with acute ischemic stroke. Acticor Biotech, a clinical stage biotech company, made the announcement today (September 26). The patient was enrolled at the CHI Memorial Stroke and Neuroscience Center, Chattanooga, Tennessee, by neurologist, Ruchir Shah. Significant potential He said: “I am very […] September 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Brainomix awarded tender to deploy AI stroke imaging across whole of Hungary Artificial intelligence (AI) stroke imaging will be deployed across centers in Hungary after Brainomix was awarded a national tender. The company was granted the tender for all stroke centers in the country as part of the National Institute for Health Development initiative to improve stroke care. Following a competitive process, the five-year program that was […] September 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Stroke drug given priority medicine status by European Medicines Agency A biotech company developing drugs for cardiovascular emergencies, specifically strokes, has received priority medicines status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab. Paris-based Acticor Biotech made the announcement yesterday (July 21) and the prime status allows reinforcement of support for the development of drugs that target an unmet medical need. It […] July 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 Acticor Biotech gets patent for cardiovascular emergency treatment product French company Acticor Biotech has announced the European Patent Office (EPO) has granted a new patent that provides protection for the use of Acticor’s product, glenzocimab in thrombotic diseases in Europe until 2036. The grant in Europe complements the ones already obtained in November 2020 in the U.S. and in November 2021 in Singapore, both […] June 30, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2022 Athersys to restructure – 70% of workforce to go U.S. biotech company Athersys, Inc. has announced a corporate restructuring plan to reduce costs and prioritize its lead clinical programs. In connection with the restructuring, the company is reducing its workforce up to 70%, with most of the reduction expected to be completed by the end of June 2022. The company said this initial step […] June 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email